New hope for aggressive lymphoma: drug cocktail aims to control High-Risk MCL
NCT ID NCT07257055
First seen Jan 07, 2026 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This phase 2 trial is testing whether adding the drug glofitamab after an initial treatment with acalabrutinib (or zanubrutinib) and rituximab can better control high-risk mantle cell lymphoma (MCL) in people who have not been treated before. The study will enroll 30 participants and primarily look at safety and side effects. The goal is to find a more effective way to manage this aggressive cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Acalabrutinib (or Zanubrutinib), Rituximab, and Glofitamab
What this could lead to
If successful, this could offer a more effective treatment approach for people with high-risk mantle cell lymphoma, potentially improving disease control without needing long-term chemotherapy.
What could go wrong
This is a small, early-phase study (30 people) focused on safety and side effects. It may not lead to a lasting benefit, and the combination of drugs could cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.